Cargando…

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies

Neutralization escape by SARS-CoV-2 variants, as has been observed in the 501Y.V2 (B.1.351) variant, has impacted the efficacy of first generation COVID-19 vaccines. Here, the antibody response to the 501Y.V2 variant was examined in a cohort of patients hospitalized with COVID-19 in early 2021 - whe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Moyo-Gwete, Thandeka, Madzivhandila, Mashudu, Makhado, Zanele, Ayres, Frances, Mhlanga, Donald, Oosthuysen, Brent, Lambson, Bronwen E., Kgagudi, Prudence, Tegally, Houriiyah, Iranzadeh, Arash, Doolabh, Deelan, Tyers, Lynn, Chinhoyi, Lionel R., Mennen, Mathilda, Skelem, Sango, Marais, Gert, Wibmer, Constantinos Kurt, Bhiman, Jinal N, Ueckermann, Veronica, Rossouw, Theresa, Boswell, Michael, de Oliveira, Tulio, Williamson, Carolyn, Burgers, Wendy A, Ntusi, Ntobeko, Morris, Lynn, Moore, Penny L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941631/ https://www.ncbi.nlm.nih.gov/pubmed/33688657 http://dx.doi.org/10.1101/2021.03.06.434193

Ejemplares similares

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)

SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
por: Wibmer, Constantinos Kurt, et al.
Publicado: (2021)

Escape from recognition of SARS-CoV-2 Beta variant spike epitopes but overall preservation of T cell immunity
por: Riou, Catherine, et al.
Publicado: (2022)

Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2022)

Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern
por: Kitchin, Dale, et al.
Publicado: (2022)

Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner
por: Keeton, Roanne, et al.
Publicado: (2021)

Enhanced neutralization potency of an identical HIV neutralizing antibody expressed as different isotypes is achieved through genetically distinct mechanisms
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2022)

Dependence on a variable residue limits the breadth of an HIV MPER neutralizing antibody, despite convergent evolution with broadly neutralizing antibodies
por: Scheepers, Cathrine, et al.
Publicado: (2022)

HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function
por: Richardson, Simone I., et al.
Publicado: (2021)

SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals
por: Richardson, Simone I., et al.
Publicado: (2022)

SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity
por: Richardson, Simone I., et al.
Publicado: (2022)

Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2023)

Infection pre-Ad26.COV2.S-vaccination primes greater class switching and reduced CXCR5 expression by SARS-CoV-2-specific memory B cells
por: Krause, Robert G. E., et al.
Publicado: (2023)

Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2023)

Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination
por: Motsoeneng, Boitumelo M., et al.
Publicado: (2023)

Reduced amplification efficiency of the RNA-dependent-RNA-polymerase target enables tracking of the Delta SARS-CoV-2 variant using routine diagnostic tests
por: Valley-Omar, Ziyaad, et al.
Publicado: (2022)

Synergistic infection of BrYV and PEMV 2 increases the accumulations of both BrYV and BrYV-derived siRNAs in Nicotiana benthamiana
por: Zhou, Cui-Ji, et al.
Publicado: (2017)

Performance of saliva and mid-turbinate swabs for detection of the beta variant in South Africa
por: Chu, Chun Yat, et al.
Publicado: (2021)

Distinct T cell functional profiles in SARS-CoV-2 seropositive and seronegative children associated with endemic human coronavirus cross-reactivity
por: Benede, Ntombi S. B., et al.
Publicado: (2023)

Author Correction: T cell responses to SARS-CoV-2 spike cross-recognize Omicron
por: Keeton, Roanne, et al.
Publicado: (2022)

T cell responses to SARS-CoV-2 spike cross-recognize Omicron
por: Keeton, Roanne, et al.
Publicado: (2022)

Antibody Isotype Switching as a Mechanism to Counter HIV Neutralization Escape
por: Scheepers, Cathrine, et al.
Publicado: (2020)

501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro
por: Liu, Haolin, et al.
Publicado: (2021)

Knowledge and uptake of occupational post-exposure prophylaxis amongst nurses caring for people living with HIV
por: Makhado, Lufuno, et al.
Publicado: (2016)

Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity
por: Tang, Haijun, et al.
Publicado: (2021)

A38 Diversity analyses of HIV-1 envelope glycoproteins in HIV-infected individuals with and without broadly neutralizing antibodies
por: Mabvakure, B., et al.
Publicado: (2017)

Corrigendum: Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity
por: Tang, Haijun, et al.
Publicado: (2021)

Live Virus Neutralisation of the 501Y.V1 and 501Y.V2 SARS-CoV-2 Variants following INO-4800 Vaccination of Ferrets
por: Riddell, Shane, et al.
Publicado: (2021)

Impact of SARS-CoV-2 exposure history on the T cell and IgG response
por: Keeton, Roanne, et al.
Publicado: (2022)

Identification and Characterization of a Novel Shigella flexneri Serotype Yv in China
por: Sun, Qiangzheng, et al.
Publicado: (2013)

Barriers to tuberculosis and human immunodeficiency virus treatment guidelines adherence among nurses initiating and managing anti-retroviral therapy in KwaZulu-Natal and North West provinces
por: Makhado, Lufuno, et al.
Publicado: (2018)

A1 The role of virus-antibody co-evolution in the development of a V3-glycan-directed HIV-1 broadly neutralizing antibody lineage
por: Kitchin, D, et al.
Publicado: (2019)

Preliminary experience with laparoscopic Foley's YV plasty for ureteropelvic junction obstruction in children
por: Nerli, Rajendra B., et al.
Publicado: (2014)

Validity and reliability of Spanish version of the EQ-i: YV[S] in Colombian children and youth
por: Navarro-Roldán, Claudia P., et al.
Publicado: (2023)

Viral Escape from HIV-1 Neutralizing Antibodies Drives Increased Plasma Neutralization Breadth through Sequential Recognition of Multiple Epitopes and Immunotypes
por: Wibmer, Constantinos Kurt, et al.
Publicado: (2013)

Increased elastase sensitivity and decreased intramolecular interactions in the more transmissible 501Y.V1 and 501Y.V2 SARS-CoV-2 variants’ spike protein–an in silico analysis
por: Pokhrel, Suman, et al.
Publicado: (2021)

Atypical molecular features of RNA silencing against the phloem-restricted polerovirus TuYV
por: Clavel, Marion, et al.
Publicado: (2021)

501Y.V2 spike protein resists the neutralizing antibody in atomistic simulations
por: Ngo, Son Tung
Publicado: (2022)

Risk Assessment in Juvenile and Young Adult Offenders: Predictive Validity of the SAVRY and SAPROF-YV
por: Kleeven, Anneke T. H., et al.
Publicado: (2020)

Unlocking the efficiency of genomics laboratories with robotic liquid-handling
por: Tegally, Houriiyah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s0q20b45e0o6jvsc65nb4dufig